Honda Giken Kogyo Kabushiki Kaisha

Mitsubishi Electric Corporation

Daiichi Sankyo Company, Limited

Daiichi Pharmaceutical Co., Ltd.

Fujifilm Corporation

Kenji Yoshikawa

Noriyasu Haginoya

Hideyuki Kanno

Tsutomu Nagata

Masatoshi Nagamochi

Yoshiko Kagoshima

Toshiharu Yoshino

Masato Suzuki

Masato Negishi

Tatsuro Yoshino

Makoto Ono

Jun Watanabe

Takayuki Baba

Hiroyuki Naito

Kenji Murata

Satoshi Komoriya

Yuko Yamamoto

Kouichi Uoto

Yasuyuki Takeda

Masashi Numata

Yuichi Tominaga

Syozo Kobayashi

Akiyoshi Mochizuki

Taeko Shinozaki

Yoshito Hamada

Toshiharu Ohta

Kouichi Kojima

Ryoichi Tanaka

Yumi Nakamoto

Masaki Kiga

Ryutaro Kanada

Eri Tokumaru

Mayumi Kitagawa

Akiko Kurimoto

Machiko Shiroishi

Tomoaki Hamada

Takafumi Oka

Katsuhisa Tanaka

Tsuyoshi Kamada

Akira Handa

Tomoya Hirata

Takuma Okuno

Masato Noshiro

Kyohei Yamakawa

Ryota Iriki

A semiconductor device production method includes providing a first electrode and a second electrode on a rear surface of a substrate where an active region emitting light is formed and providing a laminated object formed of a material less brittle than the substrate at part of a region between the first electrode and the second electrode so as to position directly below the active region; and exposing a plane on which the active region appears by cleavage of the substrate together with the laminated object in a state where the laminated object is located directly above the active region.

Semiconductor device production method

The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R, R, R, R, R, R, R, R, Ring Q, W, m and n are each as defined in the description.

Cycloalkane-1,3-diamine derivative

A method for manufacturing semiconductor devices includes: forming a plurality of semiconductor devices in a first region of a primary surface of a wafer; forming a plurality of cleave initiation portions in a second region of a primary surface different from the first region; and cleaving the wafer sequentially, using the plurality of cleave initiation portions as initiation points, starting from a cleave initiation portion that is relatively difficult to cleave among the plurality of cleave initiation portions. Forming the plurality of cleave initiation portions includes forming the plurality of first grooves by etching portions of the second region. Due to this, the yield and the manufacturing efficiency for semiconductor devices can be enhanced.

Method for manufacturing semiconductor devices

The static charge eliminator includes a charger including one or more charging units, and a grounded needle-shaped conductor. The charger is configured to charge an insulating film such that the absolute value of the surface potential of the insulating film is 3 kV or more. The needle-shaped conductor is arranged to generate a corona discharge between the needle-shaped conductor and the insulating film charged by the charger. Thereby, the static charges on the insulating film can be reliably eliminated.

Static charge eliminator and static charge elimination method

A method includes a step of forming a plurality of semiconductor devices having active regions, in a wafer, a step of forming a plurality of cleavage grooves on an upper surface side of the wafer, and a step of cleaving the wafer from the upper surface side of the wafer to expose steps formed by the plurality of cleavage grooves, and the plurality of active regions, on a sectional surface, wherein the active region is provided in a semicircle that has a radius that is a distance from a bottom of the cleavage groove to a lower surface of the wafer, and has a center that is on the lower surface of the wafer and is immediately below the cleavage groove in a cleavage propagation direction.

Method for manufacturing semiconductor device

The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R, G, T, Y, Y, Y, and Yare as defined herein.

Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors

An arithmetic processor for measuring bone density using a correspondence relationship between a luminance value of transmitted radiation and a thickness of a reference material is provided. The luminance value is obtained by applying radiation, which is emitted from a radiation source upon application of a tube voltage to the radiation source, to the reference material having different thicknesses and detecting the radiation transmitted through the reference material. The arithmetic processor includes: a generating unit that generates, based on the detected luminance value, a luminance profile representing the correspondence relationship; a normalizing unit that generates a normalized profile by normalizing the luminance profile based on a maximum value and a minimum value in the luminance profile; and a determining unit that determines whether or not each luminance value corresponding to each thickness in the normalized profile is within a range defined in advance by the tube voltage and each thickness.

Arithmetic processor and bone density measuring device

From radiation images obtained by driving radiation tube with a plurality of tube voltages, including a normal tube voltage, a density gradient with respect to at least two sections of a reference substance having different radiation transmission characteristics is obtained for each of the plurality of tube voltages prior to obtaining a bone mineral density. If a radiation image captured for obtaining a bone mineral density is determined to have been captured under a tube voltage other than the normal tube voltage, an image signal representing the image and/or a bone mineral density analysis result is corrected so as to correspond to that which should have been obtained if the image had been captured under the normal tube voltage based on the relationship between the density gradient in the image and the density gradient in the radiation image captured under the normal tube voltage.

Bone mineral density analysis method, bone mineral density analysis apparatus, and recording medium

The invention relates a compound represented by the formula (1):Q-Q-C(&#x2550;O)&#x2014;N(R)-Q-N(R)-T-Q&#x2003;&#x2003;(1)wherein Rand Rrepresent H or the like; Qrepresents an aromatic ring, heterocyclic ring or the like; Qrepresents a single bond, aromatic ring, heterocyclic ring or the like; Qrepresents a group or the like, Qrepresents an aromatic ring, heterocyclic ring or the like; and Trepresents &#x2014;CO&#x2014; or &#x2014;SO&#x2014;, and a medicine which comprises the compound and is useful for thrombosis and embolism.

Ethylenediamine derivatives

A compound represented by formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q&#x2003;&#x2003;(1)[wherein Rand Rare hydrogen atoms or the like; Qis a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Qis a single bond or the like; Qrepresents the following group: (wherein Qis an alkylene group having 1 to 8 carbon atoms, or the like); and Tand Tare carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Diamine derivatives

A compound represented by the general formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q&#x2003;&#x2003;(1)wherein Rand Rare hydrogen atoms or the like; Qis a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Qis a single bond or the like; Qis a group in which Qis an alkylene group having 1 to 8 carbon atoms, or the like; and Tand Tare carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

The invention relates a compound represented by the formula (1):Q-Q-C(&#x2550;O)&#x2014;N(R)-Q-N(R)-T-Q&#x2003;&#x2003;()wherein Rand Rrepresent H or the like; Qrepresents an aromatic ring, heterocyclic ring or the like; Qrepresents a single bond, aromatic ring, heterocyclic ring or the like; Qrepresents a groupor the like, Qrepresents an aromatic ring, heterocyclic ring or the like; and Trepresents &#x2014;CO&#x2014; or &#x2014;SO&#x2014;, and a medicine which comprises the compound and is useful for thrombosis and embolism.

A plurality of trimmed products pressed-finished products sub-component products or the like which are pre-coating stages of sheet metal parts are put on top of each other as semi-finished products and collectively packed by a rust-preventive sheet to provide a collective style of packing for collective storage This collective packing style for collective storage is stored as one packing unit. Operation timing of the collective storage is when the forecasted number of demand reaches a predetermined number, for example, when cubic volume of a metal die coincides with cubic volume for storing all quantity of the semi-finished products to be stocked. At this point, all quantity of the semi-finished products of which the demand is forecasted are collectively manufactured and stored as a stock, wherein the metal die is scrapped.

Collective and centralized inventory storing method of sheet metal parts for repairing

Growing community of inventors

Tokyo, Japan

Kenji Yoshikawa